31 reports of this reaction
2.8% of all TRIFLURIDINE reports
#4 most reported adverse reaction
COLORECTAL CANCER METASTATIC is the #4 most commonly reported adverse reaction for TRIFLURIDINE, manufactured by Sandoz Inc. There are 31 FDA adverse event reports linking TRIFLURIDINE to COLORECTAL CANCER METASTATIC. This represents approximately 2.8% of all 1,094 adverse event reports for this drug.
Patients taking TRIFLURIDINE who experience colorectal cancer metastatic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COLORECTAL CANCER METASTATIC is a less commonly reported adverse event for TRIFLURIDINE, but still significant enough to appear in the safety profile.
In addition to colorectal cancer metastatic, the following adverse reactions have been reported for TRIFLURIDINE:
The following drugs have also been linked to colorectal cancer metastatic in FDA adverse event reports:
COLORECTAL CANCER METASTATIC has been reported as an adverse event in 31 FDA reports for TRIFLURIDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
COLORECTAL CANCER METASTATIC accounts for approximately 2.8% of all adverse event reports for TRIFLURIDINE, making it a notable side effect.
If you experience colorectal cancer metastatic while taking TRIFLURIDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.